





UCLA TECHNOLOGY DEVELOPMENT GROUP

INNOVATION MAGAZINE

WINTER 2022 | VOLUME 10

TDG.UCLA.EDU

Editor:

Marivi Valcourt

Writers/

Contributors:

Charan Arora

Amir Naiberg

David Riccardo

Kristen Robertson

Matthew Savary

Peijean Ward

Designer:

Jennifer Cogan

Front Cover

Royce Hall

Photo: Alamy

CONTENTS

A message from Amir Naiberg, Associate Vice Chancellor, CEO & President	3
TDG By the Numbers	4-7
UCLA Ranks in Pitchbook and Heartland Forward Report	8
Unitary Patent Webinar Presented by Pearl Cohen	9
Opportunities for AI and computational medicine expand with launch of Optum Labs AI in Healthcare Hub	10-11
How the secrets of the 'water bear' could improve lifesaving drugs like insulin	12-13
Dual Lumen Cannula product started with UCLA Professor Abbas Ardehali	14
Former UCLA Professor finds a way to stop the bleeding	15
SILQ aims to prevent infections and continues to explore other applications	16
Therapy for ADA-SCID known as "bubble baby" disease re-starts clinical trials with state funds	17
Wine & Wisdom Inaugural Faculty Mixer	18-19
UCLA TDG Updates New Board Members, Staff Announcements	20
UCLA TDG Outreach Wrap Up	21
UCLA TDG Student Programs	22
UCLA TDG Board of Directors and Executive Staff	23



A message from

AMIR NAIBERG

Dear Readers,

In this edition of our magazine, TDG's fiscal year 2022 results are highlighted.

As we begin to exit out of more than a two-year pandemic, business has been challenging with employee shifts, inflation, and marketplace unknowns. Unfortunately, from recent investing trends it appears that 2023 will be even more challenging, especially in the biopharmaceutical field.

This fiscal year the TDG team plans to reach out to faculty members who may not be familiar with our activities, as we plan to meet about 160 faculty members in person.

Our Industry Sponsored Research grew with close to \$70M in awards. I am happy to announce that Karla Zepeda was recently promoted to Director of Industry Sponsored Research and MTA's.

In entrepreneurial news, you will read about three medical device companies receiving FDA approval: Obsidio recently acquired by Boston Scientific; SILQ recently received FDA approval for use that will fight grave infections; Spectrum Medical bringing a dual lumen cannula to the market.

Research remains strong as an example, please read about an invention of a polymer by UCLA Chemist Heather

Maynard and a newly announced partnership, born at LABEST with OPTUM Labs, aims to support the ongoing work of Artificial Intelligence (AI) in the medical field.

We held our inaugural Wine & Wisdom Faculty Mixer in November and it turned out to be a fabulous success therefore, we plan on scheduling more of these social gatherings in the near future.

Our two flagship events - the 11th Annual UCLA MedTech Partnering Conference on Tuesday, February 28, 2023, and LABEST on Thursday, May 25, 2023 are both in-person events and will be held at the UCLA Luskin Conference Center. Please be sure you register soon as they are predicted to sell out.

Wishing You Season's Greetings and a Happy Healthy New Year.

Sincerely,

Amir Naiberg


Associate Vice Chancellor, CEO & President
UCLA Technology Development Group

TDG BY THE NUMBERS


All data provided by UCLA TDG

LICENSING METRICS


TDG Gross Licensing Income (with Xtandi)




Exclusive Licenses and Options



CDA & Letters of Intent




UCLA Startups per Fiscal Year




INDUSTRY SPONSORED RESEARCH METRICS


ISR Award Totals



Material Transfer Research Agreements




Invention Disclosures




Top Invention Disclosures by school

David Geffen School of Medicine (DGSOM)



David Geffen School of Medicine	106
Pharmacology	10
Neurology	9
Med-Hematology	8
Radiology	7
Pathology	7
Other	65

Samueli School of Engineering (SEAS)























Samueli School of Engineering	110
Electrical Engineering	42
Mechanical, Aerospace & Engineering	16
Bioengineering	14
Materials Science & Engineering	11
Civil & Environmental Engineering	11
Other	16

UCLA RANKS TOP 20

Pitchbook Startup Founders

[Click on Image to see Full Rankings and Categories](#)

1		Stanford University
2		Harvard University
3		Massachusetts Institute of Technology (MIT)
4		Columbia University
5		University of California, Berkeley
6		University of Pennsylvania
7		University of Cambridge
8		University of Oxford
9		Northwestern University
10		New York University
11		University of Chicago
12		University of California, Los Angeles (UCLA)
13		Carnegie Mellon University
14		Tel Aviv University
15		INSEAD
16		University of Michigan, Ann Arbor
17		Cornell University
18		University of Texas at Austin
19		University of Southern California (USC)
20		Imperial College London

UCLA RANKS TOP 10

Heartland Forward Tech Transfer & Commercialization Report

[Click on image to read the full report](#)

RANK	INSTITUTION	INDEXED SCORE
1	Carnegie Mellon University	100
2	University of Florida	98.72
3	Columbia University	98.37
4	Stanford University	95.50
5	Harvard University	94.96
6	University of Pennsylvania	93.88
7	North Carolina State University	92.79
8	University of California, San Diego	92.64
9	University of California, Los Angeles	91.47
10	University of Minnesota	91.01
11	Massachusetts Institute Technology	90.81
12	Purdue University	90.81
13	Northwestern University	90.58
14	Cornell University	90.35
15	Duke University	88.29
16	University of Michigan	87.56
17	New York University	87.05
18	University of Washington	86.51
19	California Institute of Technology	86.36
20	University of Texas at Austin	85.97
21	University of Pittsburgh	85.78
22	Princeton University	85.62
23	Brigham Young University	84.50
24	University of Chicago	84.46
25	University of California, Berkeley	83.57

Unitary Patent Webinar

PEARL COHEN

Presented by Pearl Cohen

ON NOVEMBER 15TH, UCLA TDG hosted a webinar titled *The European Unitary Patent System is Coming into Force: What Licensees of UCLA IP need to know*

The European patent system is on the cusp of a foundational change with the Unitary Patent system, which is expected to come into force in the first half of 2023. With this change, applicants will have the option, but not obligation, to secure European patent rights through a single Unitary Patent and enforce a patent in multiple European countries in a single proceeding through the Unified Patent Court. For many, the potential significant reduction in costs could be offset by the substantial risk of a single central revocation action with effects across Europe. Licensees should understand the benefits and risks of the Unitary Patent system, and now is the time to prepare.

Pearl Cohen's Dr. Richard Korn (European patent attorney) provided insight straight out of London. View the video here <https://www.youtube.com/watch?v=DcqEFnUNuWE>



Dr. Richard M Korn

Photo: Pearl Cohen



11TH ANNUAL **UCLA MedTECH**
PARTNERING CONFERENCE

INDUSTRY INVESTORS INVENTORS

TUESDAY, FEBRUARY 28, 2023

UCLA TECHNOLOGY DEVELOPMENT GROUP

Opportunities for AI and computational medicine expand with launch of Optum Labs AI in Healthcare Hub

UCLA TECHNOLOGY DEVELOPMENT GROUP (TDG) AND OPTUM LABS, the research and development arm of UnitedHealth Group, announce the launch of a research collaboration to advance artificial intelligence (AI) and machine learning (ML) in healthcare.

AI and ML are changing how we navigate the world, from product recommendations in online shopping to real-time traffic reports on mapping apps. There is immense potential to leverage these technologies to personalize and improve the cost and quality of healthcare.

UCLA's Department of Computational Medicine spearheads a campus-wide effort to investigate AI in healthcare. The department is collaborating with Optum Labs – which, through research expertise and strategic collaborations, works to build equitable, affordable, and effective healthcare solutions leveraging big data insights, AI, and ML – to discover the future of healthcare.

Two researchers pivotal to the success of the collaboration are Dr. Eleazar Eskin and Dr. Eran Halperin.

Dr. Eleazar Eskin, inaugural chair for the UCLA Department of Computational Medicine, has worked to better patient care through artificial intelligence and genomics. His discoveries in the lab are applied to some patients through UCLA Health.

Dr. Eran Halperin, is currently on leave as Professor of Computer Science, Computational Medicine, Anesthesiology, and Human Genetics at UCLA and has recently joined Optum Labs as Senior Vice President of Artificial Intelligence and Machine Learning. Dr. Halperin's work focuses on machine learning in medicine and computational genomics.

In addition to Dr. Eskin and Dr. Halperin, dozens of UCLA researchers are studying AI, genomics, image analysis, prediction models, algorithms, sensors, and more. UCLA's unique strength of having a prestigious medical



Eleazar Eskin



Eran Halperin

Photos: UCLA

school, a world-class research hospital, and a nationally ranked engineering school accelerates efforts to improve patient treatment. Through the collaboration with Optum Labs, these researchers have the opportunity to expand their studies.

The collaboration between UCLA Technology Development Group's Industry Sponsored Research department (TDG-ISR) and Optum Labs includes a joint steering committee with initial funding of \$1M from Optum Labs.

UCLA TDG CEO Amir Naiberg comments, "This collaboration was born at LABEST (Los Angeles Bioscience Ecosystem Summit Twenty twenty-two - the annual UCLA

"Working together with academia and research institutions, we will accelerate advances in equitable, personalized healthcare through the strategic application of responsible Machine Learning and Artificial Intelligence."

Ranju Das, CEO of Optum Labs

Opportunities for AI continued

bioscience conference). We were happy to host Ranju Das, CEO of Optum Labs, and his leadership team at a round table discussion during the conference. We are excited to create a collaboration that will bring AI closer to helping patients. “

“UCLA’s world-class faculty combined with Optum Labs’ reach and expertise create a tremendous opportunity to make healthcare better for everyone through the applications of the latest AI and ML technology,” said Rahul Bhotika, Senior Vice President of Research at Optum Labs. “This Optum Labs AI in Healthcare Hub is the beginning of a collaborative research effort set to drive great impact in the future of healthcare.”

“The Optum Labs AI in Healthcare Hub, in partnership with UCLA, supports UnitedHealth Group’s mission – helping people live healthier lives,” said Ranju Das, CEO of Optum Labs. “Working together with academia and research institutions, we will accelerate advances in equitable, personalized healthcare through the strategic application of responsible Machine Learning and Artificial Intelligence.”



Photo: [AILA](#)

The AI in Healthcare Hub kicked off
Dec 6, 2022 at UCLA Mong Auditorium

INNOVATION FUND



UCLA created the Innovation Fund to bridge the gap between early-stage research and translation of life-impacting technology.

[LEARN MORE](#)

How the secrets of the 'water bear' could improve lifesaving drugs like insulin

Inspired by creatures that survive in harsh environments and aided by UCLA's Innovation Fund, a team has invented polymer with the potential to extend the shelf life and reach of medications

By Wayne Lewis

UCLA CHEMIST HEATHER MAYNARD had to wonder: How do organisms like the tardigrade do it?

This stocky microscopic animal, also known as a water bear, can survive in environments where survival seems impossible. Tardigrades have been shown to endure extremes of heat, cold and pressure — and even the vacuum of space — by entering a state of suspended animation and revitalizing, sometimes decades later, under more hospitable conditions.

“Trehalose polymers stabilize a wide range of proteins and enzymes. Vaccines are a possibility, and we think that the polymers could be a platform technology applied to an array of different biologically based drugs.”

- Heather Maynard

If she could understand the mechanism behind this extraordinary preservation, Maynard reckoned, she might be able to use the knowledge to improve medicines so that they remain potent longer and are less vulnerable to typical environmental challenges, ultimately broadening access and benefiting human health.

It turns out that one of the process protecting tardigrades is spurred by a sugar molecule called trehalose, commonly found in living things from plants to microbes to insects, some of which use it as blood sugar. For a few select organisms, such as the water bear and the spiky resurrection plant, that can revive after years of near-zero metabolism and complete dehydration, trehalose's stabilizing power is the secret to their unearthly fortitude.



Heather Maynard

Photo: Heather Maynard

Armed with this insight, Maynard, a professor of chemistry and biochemistry who holds UCLA's Dr. Myung Ki Hong Chair in Polymer Science, invented a polymer based on the sugar. Her polymer, called poly(trehalose methacrylate), or pTrMA, actually seems to improve upon nature in its ability to render drugs more robust to the ravages of time and temperature.

“We figured that if trehalose could stabilize entire organisms, that makes it a pretty good stabilizer,” said Maynard, who is also the associate director of technology and development at the California NanoSystems Institute at UCLA. “However, that our polymer outperformed trehalose was not expected.”

With support and guidance from the UCLA Innovation Fund, a program designed to facilitate the commercial-

‘Water bear’ continued

ization of UCLA-owned therapies and other health-related technologies, Maynard and her team opted to investigate pTrMA’s effects on insulin, a World Health Organization “essential medicine” that many people with diabetes inject daily to manage the disease.

When exposed to heat or shaken up too much, insulin proteins can clump in ways that gum up needles, make the medicine less effective or even prompt a harmful reaction from the body’s natural defenses. As a result, insulin must be handled with care and transported in refrigerated compartments.

Accordingly, insulin that remains stable for longer without refrigeration could reduce the drug’s cost by making logistics less expensive. And an extended shelf life would cut back on both wasted medicine and potentially dangerous situations where expired insulin delivers an inadequate dose. More than that, insulin could become accessible to some remote locales that are currently out of reach for refrigerated transport.

A series of studies led by Maynard over the last three years has demonstrated pTrMA’s potential. A recent Innovation Fund–supported study published in ACS Applied Materials & Interfaces found that the polymer preserved insulin at temperatures of nearly 200 degrees Fahrenheit — close to water’s boiling point — and through almost a year of refrigerated storage, with 87% of the medication remaining intact, compared with less than 8% of insulin alone. Laboratory experiments into pTrMA’s safety showed that it did not trigger an immune response in mice.

A 2021 study, also backed by the Innovation Fund, showed that insulin plus pTrMA has a low enough viscosity to be safely injected, and 2020 research demonstrated that a version of pTrMA designed to degrade inside the body retained the ability to stabilize insulin.

An early finding, from 2014, that pTrMA actually works better than trehalose as a preserving agent hasn’t been the only pleasant surprise along the way. Maynard’s team typically designs polymers to be chemically linked to drug molecules, but in the case of pTrMA, they found that it is equally effective intermingled alongside insulin molecules without chemical links.

Maynard suspects that the polymer has potential for broader use.



Photo: iStock.com/dottedhippo

A tardigrade, or water bear, floating in water. The tiny organism can endure some of the most extreme conditions on Earth — and even space.

“Trehalose polymers stabilize a wide range of proteins and enzymes,” she said. “Vaccines are a possibility, and we think that the polymers could be a platform technology applied to an array of different biologically based drugs.”

Flexible resources from the Innovation Fund have allowed Maynard the freedom to pursue the most relevant questions in her studies. That benefit ended up working in concert with another: introductions to pharmaceutical industry experts by UCLA’s Technology Development Group.

One such expert recommended that Maynard investigate the action of the pTrMA in the body. In her recent ACS Applied Materials & Interfaces publication on pTrMA, Maynard and her team found no significant difference in blood plasma concentrations over time between insulin alone and the drug formulated with pTrMA.

“It’s not always easy to find funding for some of the systematic studies we’ve been conducting,” Maynard said. “The UCLA Innovation Fund accelerated the research and gave us the ability to pivot.”

If Maynard’s polymer finds continued success as a safe stabilizer, drugs from the lifesaving to the everyday could become cheaper and available in more places. And she’ll have a couple of others to thank: Mother Nature and the nigh-indestructible water bear.

[Original Story appeared in UCLA Newsroom](#)

Dual Lumen Cannula product started with UCLA Professor Abbas Ardehali

UCLA PROFESSOR OF SURGERY AND MEDICINE

ABBAS ARDEHALI MD is a cardiothoracic surgeon and director of the UCLA Heart-Lung transplant program. He is the lead Principal Investigator and world renowned for the “breathing lung” technology where a donated lung is kept warm and “alive” while being transported.

Dr. Ardehali has spent years researching heart and lung transplantation and recently developed a dual lumen cannula for use in extracorporeal membrane oxygen-

“It will improve oxygen delivery in patients with lung failure and improve heart support in patients with right ventricle failure”

- Abbas Ardehali MD

ation (ECMO) procedures. ECMO happens when blood is pumped outside of your body to a heart-lung machine that removes carbon dioxide and sends oxygen-filled blood back to tissues in the body.

The benefits of this dual lumen cannula include the increased stability of placement through single site insertion and better fluid flow design resulting in improved patient outcomes.

The dual lumen cannula is also compatible with available insertion products.

“It will improve oxygen delivery in patients with lung failure and improve heart support in patients with right ventricle failure,” explains Ardehali.

Ardehali also provided a real-world example of a 27-year-old patient whose lungs were failing from COVID-19 and



Abbas Ardehali MD

Photo: UCLA

needed a lung transplant to survive. The catheters that were being used at another facility were not sufficient in providing oxygen. The patient was transferred to UCLA and Ardehali used the cannula that he invented, and since, the patient successfully received a lung transplant and after 4 months, he has improved significantly.

The dual lumen cannula has been cleared by the FDA and is now available for commercial sale. UCLA Technology Development Group granted the exclusive license of this technology to Spectrum Medical.

[See Details on Dual Lumen Cannula Here](#)



Photo courtesy of Spectrum Medical

Former UCLA Professor finds a way to stop the bleeding

THERE ARE ALREADY COIL BEADS AND LIQUIDS on the market that target embolization - a procedure that can be used to stop bleeding or block the flow of blood, but these products posed some challenges such as breakage, rejection and missed targets. Dr. Ali Khademhosseini is a professor of bioengineering who was already working with gels in other applications. When posed with the problem of hemorrhaging and stopping blood flow to tumors, the idea of using a gel material for the purpose of embolization came to fruition. "I was

"I was already working with gels and I understood the challenges of current embolization procedures and said 'let's try it' since this type of material could solve the challenges that other products posed for patients."

- Dr. Ali Khademhosseini

already working with gels and I understood the challenges of current embolization procedures and said 'let's try it' since this type of material could solve the challenges that other products posed for patients", said Khademhosseini.

It took several years of research starting at Harvard University where Khademhosseini was a professor at Harvard Medical School (HMS) and faculty at the Harvard-MIT's Division of Health Sciences and Technology (HST). In 2017, he joined UCLA as the Levi Knight Professor of Bioengineering, Chemical Engineering, and



Ali Khademhosseini

Photo: Terasaki Institute

Radiology at UCLA. He was the Founding Director of the Center for Minimally Invasive Therapeutics at UCLA. Currently, Dr. Khademhosseini is the CEO of Terasaki Institute for Biomedical Innovation based in Westwood Village.

Time is always of the essence with critical procedures and Khademhosseini's team forwarded the idea of preparing the gel in ready-to-use form. Similar to the idea of toothpaste consistency, the gel maintains its shape and stays in the body that forms a permanent tissue and permanently blocks blood flow to a particular area.

In 2018, the company Obsidio was founded by Khademhosseini, Ehsan Jabbarzadeh and Rahmi Oklu around the technology named GEM™ or Gel Embolic Material, licensed from UCLA -TDG. GEM technology recently received clearance by U.S. Food and Drug Administration (FDA). By August 2022, Obsidio was acquired by [Boston Scientific Corporation](#).

SILQ aims to prevent infection and continues to explore other applications



THE UCLA RESEARCH TEAM OF DR. RICHARD KANER AND DR. BRIAN MCVERRY from the Chemistry & Biochemistry department developed a coating solution that helps prevent infections from medical devices placed in the body. The most common devices that can cause infections are catheters, stents, lines, implants, and multiple other medical devices. By treating these various devices, bacteria and fungus growth and blood clots are deterred.

Kaner, McVerry and Dr. Jack Kavanaugh, who is CEO and Chairman co-founded the company SILQ around this technology. The team then got to work on practical ways to tackle infections.



Jack Kavanaugh

Photo: SILQ

FDA approval was granted to SILQ for urinary catheters that are pre-treated with the solution and packaged as ready-to-use. The company is in the process of demonstrating the product's effectiveness with use in the field at institutions such as the VA, Rancho Los Amigos and USC.

Through the researchers' work, they looked at expanding SILQ's use to multiple medical and other non-medical applications. The company will also be addressing

"The problem is that these infections have been traditionally treated by anti-biotics and as we know this method becomes ineffective after time," said Kavanaugh "and so the idea was to prevent these infections."



Richard Kaner



Brian McVerry

Photos: UCLA

applications for water desalination, water filters, other medical and industrial applications. The general principal is to coat these various items with SILQ's product to improve performance and life span.

Kavanaugh concludes, "I'm excited about the potential benefits and social impact of SILQ's applications and I'm looking forward to help the company grow."

Read more about SILQ in [UCLA Newsroom](#)

Visit [SILQ website](#)

Don't miss #UCLAMedTech2023 Conference featuring a Fireside Chat with Dr. Richard Kaner on Tue. Feb 28, 2023 – [Register Today!](#)




Image: SILQ

Therapy for ADA-SCID known as “bubble baby” disease re-starts clinical trials with state funds

UCLA TDG currently seeking partners

ADENOSINE DEAMINASE SEVERE COMBINED IMMUNODEFICIENCY OR ADA-SCID FOR SHORT is a rare, pediatric, genetic disorder that is inherited. The genetic disorder results in low levels of the ADA enzyme that prevents cells from dividing and developing in a normal way. This leads to a child being susceptible to many infections and diseases with no immunity and no ability for the body to fight infections. The was coined “bubble baby” due to an old method of patients being kept in plastic to prevent infection.

UCLA distinguished professor, Donald Kohn, produced a potential cure for ADA-SCID with initial clinical trials providing 100% overall survival. The original license was terminated by a British based therapeutics company which halted clinical trials, commercial advancement,



Photo: UCLA

Donald Kohn

and related funding. Now CIRM (California Institute of Regenerative Medicine) has provided \$5.8M in funding support which re-started the clinical trials for a few young patients.

UCLA TDG is currently seeking partners who will complete development and commercialization of this important ADA-SCID therapy. It is an opportunity to bring the cure to thousands of children who suffer from this condition worldwide. Contact [Mark Wisniewski](#), Senior Director Bio Pharmaceuticals, UCLA TDG for more information.

SAVE THE DATE

UCLA MEYER AND
RENEE LUSKIN
CONFERENCE CENTER



MAY 24-25, 2023

LA
BIOSCIENCE
ECOSYSTEM
SUMMIT
TWENTY23™
UCLA

WINE & WISDOM

Inaugural Faculty Mixer

UCLA TDG HOSTED ITS FIRST WINE & WISDOM FACULTY MIXER last month and the event was a wonderful success. With over 70 attendees, the evening kicked off with presentations by TDG's Mark Wisniewski who provided an overview of tech transfer, followed by Will Wood from Gates & Cooper who went through IP basics and concluded with Judy Fortin who provided expert tips on pitching your idea. Several venture capital representatives met with many UCLA

Faculty to get updates on their research projects and discuss potential funding. And the last hour of the event featured wine, appetizers and great conversation among all the guests.

Sign up for the [UCLA TDG Newsletter](#) or Follow us on [LinkedIn](#) to stay up to date on the next Wine & Wisdom Faculty Mixer!



Presentations and Networking at Wine & Wisdom

Photos: UCLA TDG

WINE & WISDOM

Inaugural Faculty Mixer



Over 40 UCLA Faculty and Lab Staff attended Wine & Wisdom

Photos: UCLA TDG

NEW BOARD MEMBERS

ANDREI IANCU WAS NAMED CHAIRMAN OF THE UCLA TDC BOARD. In addition, we welcomed new board members Mert Atkar, Head of Corporate Development, Kite, a Gilead Company, Lauren Schoppe, Founder, Fuentek and Cat Oyler, Vice President, Global Head Clinical Excellence and Transformation(CET), Janssen Immunology.

We would like to thank William Mitchell Chairman Emeritus, Barbara Sosnowski and Aya Jakobovits for their dedication and service. We also want to remember Carl Gulbrandsen, who passed away in October. He was a trailblazer of tech transfer at WARF (Wisconsin Alumni Research Foundation) and served on the TDG Board for many years.



Andrei Iancu

Chairman of the
UCLA TDC Board



Mert Atkar

Head of Corporate
Development,
Kite, a Gilead Company



Lauren Schoppe

Founder, Fuentek



Cat Oyler

Vice President, Global
Head Clinical Excellence
and Transformation(CET),
Janssen Immunology


STAFF ANNOUNCEMENTS

Welcomes and Promotions



Sierra Jenkins

Industry Sponsored
Research and Material
Transfer, Coordinator




Diane Karapetian

Industry Sponsored
Research and Material
Transfer, Associate



PJ Ward

Business Development
Associate -
Life Sciences



Karla Zepeda

promoted to
Director of the Industry
Research and Material
Transfer

Photos: UCLA TDG

UCLA TDG OUTREACH WRAP UP



Attendees enjoying the LABEST 2022 Conference

Photos: UCLA TDG

UCLA TECHNOLOGY DEVELOPMENT GROUP hosted both the UCLA MedTech and LABEST (Los Angeles Bio-science Ecosystem Summit 2022) conferences in person last March and May 2021. Attendance was robust for both conferences with over 400 attending MedTech and 1000 attending LABEST. Sessions from the conferences can be viewed on our [YouTube Channel](#).

We hosted the Unitary Patent webinar that featured Dr. Richard Korn from Pearl Cohen. He went into detail on the changes and options for European patents. If you are a UCLA Licensee who didn't make the original session, please see the video archive [here](#).

We kicked off our first Wine & Wisdom Faculty Mixer in November. You can read more on page 18.

The UCLA TDG website tdg.ucla.edu continues to serve as a resource for our researchers and community. Make sure you take a look at some new and updated pages including our [Pitch Gym](#), New Ventures, [In-Part funding opportunities](#). Budding Bruin entrepreneurs can visit

the [TDG Hub](#) where you can view both on-campus and ecosystem associations, partner service vendors and funding leads.

Look out for the [UCLA Innovation Fund](#)'s open call for applications in early 2023. The fund supports early-stage projects.

As we head into 2023, make sure to block off your calendar for the [11th Annual MedTech Partnering Conference](#) will take place in person Tue. Feb 28, 2023. Register today at the \$35 rate before prices go up January 1st. [LABEST 2023](#) is scheduled for Thursday, May 25, 2023. Both flagship events will be held at the UCLA Luskin Conference Center.

[LinkedIn](#) and [Instagram](#) will be our main social media platforms so if you don't already follow us, please do. Also, [sign up](#) for our UCLA TDG e-newsletter to get the most updated details on what's happening with UCLA research and entrepreneurs.


UCLA TDG STUDENT PROGRAMS

THE TDG STUDENT PROGRAMS offer graduate and undergraduate students paid internships that offer in-depth, hands-on experience in the business of technology transfer and intellectual property management. Along with real-world job skills, the program exposes fellows to new, meaningful career opportunities related to transferring inventions from the lab to the marketplace and, ultimately, to changing the lives of people worldwide through science. Among the skills the fellows acquire are technology evaluation, marketing and business development and tech commercialization. During this unique experience, fellows actively contribute to the commercialization of UCLA technologies.

PHYSICAL SCIENCE TECH FELLOWS



Roshan Plamthottam
Senior Tech Fellow - Physical Sciences
Ph.D. Materials Sciences and Engineering



Zachary Hern
Department of Chemistry
& Biochemistry
Ph.D.



Zhou Li
SEAS, Civil Engineering
PhD

LIFE SCIENCE TECH FELLOWS



Kathleen Chen
Senior Tech Fellow - Life Sciences
Department of Chemistry & Biochemistry
Ph.D.



Clara T. Cano
Molecular Biology Institute,
Department of Biological Chemistry
Ph.D. in Molecular Biology



Alfredo Enrique Gonzalez
Graduate Program in Bioscience-Department
of Molecular and Medical Pharmacology
Ph.D. in Molecular and Medical Pharmacology

NEW VENTURES TECH FELLOWS

Rajashree Bhattacharya
Clincy Cheung
Simran Masand
Kshitija Shah
Alex Wasdahl
Eunice Ye



Yan Li
Department of Biological Chemistry
Ph.D.



Abril Morales
Molecular Biology
Ph.D.

Photos: Provided by each tech fellow

UCLA TDG BOARD OF DIRECTORS

ANDREI IANCU, CHAIRMAN

Partner, Irell & Manella LLP

MERT AKTAR

Head of Corporate Development, Kite, a Gilead Company

FABRIZIO BONANNI

Executive Vice President, Amgen (Retired)

MICHAEL J. CLEARE

Associate Vice Provost for Research, University of Pennsylvania

GAY CROOKS

Director, Cancer and Stem Cell Biology Program, Jonsson Comprehensive Cancer Center at UCLA

MICHAEL DAL BELLO

Investment Partner of Healthcare at Pritzker Group Private Capital

SYLVIO DROUIN

Vice President, Research Labs Unity Technology

CRAIG EHRLICH

Investor, Entrepreneur

DAVID GILMAN

Chief Business & Strategy Officer, ADC Therapeutics

THOMAS HERGET

Head, Silicon Valley Innovation Hub

EVA HO

Partner, Fika Ventures

RAJIT MALHOTRA

Executive Chairman, AmperSand Biopharmaceuticals

JOHN T. MAPES

Managing Partner, Aurora Capital Partners

WILLIAM MITCHELL, CHAIRMAN EMERITUS

Founding Partner, Sequel Venture Partners, LLC

AL OSBORNE

Senior Associate Dean, External Affairs, UCLA Anderson School of Management

CAT OYLER

Vice President, Global Head, Clinical Excellence and Transformation Vice President, Integration Leader – Momenta Pharmaceuticals

ROBERT PACIFICI, PH.D.

Chief Scientific Officer, CHDI Foundation

MATT PENDO

Oaktree

JESSICA RICHTER

Chief Operating Officer, Experien Group

ANNE W. RIMOIN

Gordon-Levin Endowed Chair in Infectious Diseases and Public Health, UCLA Fielding School of Public Health

LAURA SCHOPPE

Founder, Fuentek

TOM UNTERMAN, CHAIRMAN EMERITUS

Founding Partner, Rustic Canyon Partners

UCLA TDG EXECUTIVE STAFF

AMIR NAIBERG

Associate Vice Chancellor – CEO and President

TIM GRAUERHOLZ

Chief Financial Officer and Chief Operations Officer

DINA LOZOFISKY

Senior Director of Physical Sciences and Engineering

MARK WISNIEWSKI

Senior Director of Biopharmaceuticals

THOMAS LIPKIN

Director of UCLA Innovation Fund and New Ventures

LAURA VAN NOSTRAND

Director of Human Resources

KARLA ZEPEDA

Director of Industry Research and Material Transfer



UCLA TECHNOLOGY DEVELOPMENT GROUP (TDG) promotes UCLA innovation, research, education and entrepreneurship to benefit society. Working with UCLA TDG helps facilitate the translation of UCLA discoveries into new products and services that create economic value to support UCLA's scholarly and educational missions. The UCLA TDG office manages a large portfolio of technologies and license agreements and has a rich history of startup company formation.

CONNECT WITH UCLA TDG:

Visit us at tdg.ucla.edu

Contact us at marketing@tdg.ucla.edu

Connect with us [@UCLATDG](https://twitter.com/UCLATDG)



UCLA Technology Development Group
10889 Wilshire Blvd. Suite 920
Los Angeles, CA 90095
310-794-0558